Stockreport

Generation Bio Reports Recent Business Highlights and Third Quarter 2024 Financial Results

Generation Bio Co. - Common stock  (GBIO) 
PDF Non-human primate data presented at ESGCT demonstrated selective in vivo delivery of mRNA with T cell-targeted lipid nanoparticle (ctLNP) Cash balance of $199.8 million [Read more]